Clinicopathological Characteristics and Risk Factors for Rapid eGFR Decline in Chinese Patients with Biopsy-Proven Obesity-Related Glomerulopathy

References

• NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–1396. doi:10.1016/S0140-6736(16)30054-X
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou B, Zhao Z, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18. Lancet. 2021;398(10294):53–63. doi:10.1016/S0140-6736(21)00798-4
   PubMed Web of Science ®Google Scholar
• Hu R, Quan S, Wang Y, et al. Spectrum of biopsy proven renal diseases in central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994. doi:10.1038/s41598-020-67910-w
   PubMed Web of Science ®Google Scholar
• Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol. 2010;5:1401–1409. doi:10.2215/CJN.01370210
   PubMed Web of Science ®Google Scholar
• Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992;20(6):629–634. doi:10.1016/S0272-6386(12)70230-5
   PubMed Web of Science ®Google Scholar
• Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis. 1987;10(6):470–472. doi:10.1016/S0272-6386(87)80196-8
   PubMed Web of Science ®Google Scholar
• Goumenos DS, Kawar B, El Nahas M, et al. Early histological changes in the kidney of people with morbid obesity. Nephrol Dial Transplant. 2009;24(12):3732–3738. doi:10.1093/ndt/gfp329
   PubMed Web of Science ®Google Scholar
• Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology. 2001;69(2):113–118. doi:10.1159/000048764
   PubMed Web of Science ®Google Scholar
• Yang S, Cao C, Deng T, Zhou Z. Obesity-related glomerulopathy: a latent change in obesity requiring more attention. Kidney Blood Press Res. 2020;45(4):510–522. doi:10.1159/000507784
   PubMed Web of Science ®Google Scholar
• Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–1509. doi:10.1046/j.1523-1755.2001.0590041498.x
   PubMed Web of Science ®Google Scholar
• Praga M, Hernández E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16(9):1790–1798. doi:10.1093/ndt/16.9.1790
   PubMed Web of Science ®Google Scholar
• Tsuboi N, Koike K, Hirano K, Utsunomiya Y, Kawamura T, Hosoya T. Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy. Clin Exp Nephrol. 2013;17(3):379–385. doi:10.1007/s10157-012-0719-y
   PubMed Web of Science ®Google Scholar
• Chen HM, Li SJ, Chen HP, Wang QW, Li LS, Liu ZH. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis. 2008;52:58–65. doi:10.1053/j.ajkd.2008.02.303
   PubMed Web of Science ®Google Scholar
• Oshima M, Shimizu M, Yamanouchi M, et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021;17(11):740–750. doi:10.1038/s41581-021-00462-y
   PubMed Web of Science ®Google Scholar
• Sumida K, Kovesdy CP. Disease trajectories before ESRD: implications for clinical management. Semin Nephrol. 2017;37(2):132–143. doi:10.1016/j.semnephrol.2016.12.003
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 2: definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63–72. doi:10.1038/kisup.2012.65
   Google Scholar
• Chen H, Liu Z, Li S, et al. The relationship between body fat distribution and renal damage in Chinese with obesity. Exp Clin Endocrinol Diabetes. 2008;116:99–103. doi:10.1055/s-2007-992117
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Lotan Y, Zhang J, et al. Triglycerides in the human kidney cortex: relationship with body size. PLoS One. 2014;9:e101285. doi:10.1371/journal.pone.0101285
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, et al. Validation of the oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–836. doi:10.1038/ki.2014.63
   PubMed Web of Science ®Google Scholar
• Hung PH, Hsu YC, Chen TH, Lin CL. Recent advances in diabetic kidney diseases: from kidney injury to kidney fibrosis. Int J Mol Sci. 2021;22(21):11857. doi:10.3390/ijms222111857
   PubMed Web of Science ®Google Scholar
• Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278(5):F817–F822. doi:10.1152/ajprenal.2000.278.5.F817
   PubMed Web of Science ®Google Scholar
• Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23(12):3946–3952. doi:10.1093/ndt/gfn379
   PubMed Web of Science ®Google Scholar
• de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43:41–47.
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Chen YP, Yang M, et al. Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes. Mol Med Rep. 2018;17:4589–4598. doi:10.3892/mmr.2018.8386
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhong X, Li N, Pan T. Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway. Obes Res Clin Pract. 2019;13:385–390. doi:10.1016/j.orcp.2019.03.003
   PubMed Web of Science ®Google Scholar
• Zhao J, Rui HL, Yang M, Sun LJ, Dong HR, Cheng H. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy. Mediators Inflamm. 2019;2019:3172647. doi:10.1155/2019/3172647
   PubMed Web of Science ®Google Scholar
• de Vries AP, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2:417–426. doi:10.1016/S2213-8587(14)70065-8
   PubMed Web of Science ®Google Scholar
• Xuan Y, Zhang W, Wang Y, et al. The association between hypertriglyceridemic-waist phenotype and chronic kidney disease in patients with type 2 diabetes: a cross-sectional METAL study. Diabetes Metab Syndr Obes. 2022;15:1885–1895. doi:10.2147/DMSO.S359742
   PubMed Web of Science ®Google Scholar
• Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessì-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens. 2012;25:818–826. doi:10.1038/ajh.2012.47
   PubMed Web of Science ®Google Scholar
• Shimada H, Noro E, Suzuki S, et al. Effects of adipocyte-derived factors on the adrenal cortex. Curr Mol Pharmacol. 2020;13:2–6. doi:10.2174/1874467212666191015161334
   PubMed Web of Science ®Google Scholar
• Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831–843. doi:10.1097/HJH.0b013e3282f624a0
   PubMed Web of Science ®Google Scholar
• Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria. Nefrologia. 2015;35:554–561. doi:10.1016/j.nefro.2015.09.008
   PubMed Web of Science ®Google Scholar
• Yasue S, Masuzaki H, Okada S. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens. 2010;23:425–431. doi:10.1038/ajh.2009.263
   PubMed Web of Science ®Google Scholar
• Mottl AK, Buse JB, Ismail-Beigi F, et al. Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes. Clin J Am Soc Nephrol. 2018;13:1693–1702. doi:10.2215/CJN.06200518
   PubMed Web of Science ®Google Scholar
• Frazier R, Mehta R, Cai X, et al. Associations of fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes. Kidney Int Rep. 2019;4:94–102. doi:10.1016/j.ekir.2018.09.006
   PubMed Web of Science ®Google Scholar
• Oscarsson J, Önnerhag K, Risérus U, et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018;12:1390–1403.e1394. doi:10.1016/j.jacl.2018.08.003
   PubMed Web of Science ®Google Scholar
• Munkhaugen J, Lydersen S, Widerøe TE, Hallan S. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis. 2009;54:638–646. doi:10.1053/j.ajkd.2009.03.023
   PubMed Web of Science ®Google Scholar
• Pehlivan E, Ozen G, Taskapan H, Gunes G, Sahin I, Colak C. Identifying the determinants of microalbuminuria in obese patients in primary care units: the effects of blood pressure, random plasma glucose and other risk factors. J Endocrinol Invest. 2016;39:73–82. doi:10.1007/s40618-015-0331-6
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–3315. doi:10.2337/db12-1814
   PubMed Web of Science ®Google Scholar
• Bilha SC, Nistor I, Nedelcu A, et al. The effects of bariatric surgery on renal outcomes: a systematic review and meta-analysis. Obes Surg. 2018;28:3815–3833. doi:10.1007/s11695-018-3416-4
   PubMedGoogle Scholar
• Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961. doi:10.1136/bmj.g3961
   PubMedGoogle Scholar
• Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–315. doi:10.1007/s11695-009-0026-1
   PubMed Web of Science ®Google Scholar
• Fenske WK, Dubb S, Bueter M, et al. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9:559–568. doi:10.1016/j.soard.2012.03.009
   PubMed Web of Science ®Google Scholar
• Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772–779. doi:10.1053/j.ajkd.2006.07.025
   PubMed Web of Science ®Google Scholar
• Chen X, Chen S, Li Z, et al. Correlation of body mass index with clinicopathologic parameters in patients with idiopathic membranous nephropathy. Diabetes Metab Syndr Obes. 2022;15:1897–1909. doi:10.2147/DMSO.S366100
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79:219–230. doi:10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–515. doi:10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Guo H, Wang B, Li H, Ling L, Niu J, Gu Y. Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes. Am J Physiol Renal Physiol. 2018;314:F181–F189. doi:10.1152/ajprenal.00302.2017
   PubMed Web of Science ®Google Scholar